Market Herald logo

Subscribe

Be the first with the news that moves the market

HeraMED limited expand its HeraBEAT product after launching a UK website. The med-tech company’s product allows mothers and doctors to monitor infant heart rates during pregnancy.

HeraBEAT was previously unavailable to UK consumers but available in Israel. HeraMED assesses 770,000 UK births annually, making this expansion their largest market entry yet.

The expansion was made after positive feedback from UK doctors and Israeli consumers. The product also features an integrated mobile app.

Professional discussion included feedback from senior obstetricians and gynecologists in public hospitals and private medical institutions.

HeraMED CEO David Groberman says the company is well ahead of commercial scale.

“[The company] is progressing discussions with a number of parties globally to progress its international expansion, [we look] forward to updating shareholders on these developments in the coming months,” he said.

The company plans to use UK revenue for further expansion across Europe.

The company is currently in discussion with more medical institutions to strengthen professional use.

HeraMED plans for global expansion in the coming months.

Please see the announcement

HMD by the numbers
More From The Market Herald
Paradigm Biopharmaceuticals (ASX:PAR) - CEO, Marco Polizzi

" Paradigm Biopharmaceuticals (ASX:PAR) enters trading halt amid cap raise

Paradigm Biopharmaceuticals (ASX:PAR) has entered into a trading halt ahead of a capital raise.
HITIQ (ASX:HIQ) - CEO, Mike Vegar

" HITIQ (ASX:HIQ) secures third Australian innovation patent

HITIQ (ASX:HIQ) has secured a third Australian innovation patent related to its virtual reality (VR) concussion…

" Medlab Clinical (ASX:MDC) sees depression patent accepted in Europe

Medlab Clinical's (ASX:MDC) patent for depression is formally accepted by the European Patent Office.
The Market Herald Video

" Patrys (ASX:PAB) confirms PAT-DX1 improves efficacy of radiation therapy

Patrys (ASX:PAB) has released pre-clinical data for an animal study of its lead PAT-DX1 product showing…